REPATH LIMITED

Active United Kingdom

Specialists medical practice activities

0 employees website.com
Specialists medical practice activities
R

REPATH LIMITED

Specialists medical practice activities

Founded 18 Feb 2002 Active United Kingdom 0 employees website.com
Specialists medical practice activities
Accounts Submitted 16 Dec 2025 Next due 31 Dec 2026 7 months remaining
Confirmation Submitted 13 Apr 2026 Next due 12 Apr 2027 10 months remaining
Net assets £26K £48K 2024 year on year
Total assets £40K £48K 2024 year on year
Total Liabilities £14K £550 2024 year on year
Charges None No charges registered

Contact & Details

Contact

Full company profile for REPATH LIMITED (04375578), an active company based in United Kingdom. Incorporated 18 Feb 2002. Specialists medical practice activities. View financials, directors, shareholders, and filings.

Business Summary

This company specializes in providing innovative solutions and services across multiple sectors.

Products & Services

consulting software analytics integration

Reports

Credit Report

In-depth credit score, financial analysis, risk assessment and company intelligence.

Financials

Financials

Period 1 Apr → 31 Mar 2025
Type total-exemption-full
Next accounts 31 Mar 2026
Due by 31 Dec 2026 7 months remaining

Net Assets, Total Assets & Total Liabilities (2013–2024)

Cash in Bank

£31.29k

Decreased by £42.65k (-58%)

Net Assets

£26.06k

Decreased by £48.19k (-65%)

Total Liabilities

£13.62k

Increased by £550.00 (+4%)

Turnover

N/A

Employees

N/A

Debt Ratio

34%

Increased by 19 (+127%)

Financial History

Revenue, profit, EBITDA and key financial figures

2025
31 Mar Year End
2023
31 Mar Year End
P&L
Revenue
£142.3M
£128.7M
Gross Profit
£48.2M
£43.1M
Operating Profit
£22.4M
£19.8M
Net Profit
£18.1M
£15.9M
EBITDA
£31.5M
£28.2M
Assets
Cash
£24.7M
£21.3M
Total Assets
£89.4M
£82.1M
Liabilities
Total Liabilities
£45.2M
£41.8M
Key Metrics
Employees
1,247
1,156
Latest Revenue
£142.3M
Latest EBITDA
£31.5M
Cash Position
£24.7M

Funding

Fundraising & Grants

No fundraising or grants recorded

Investors (0)

No investor information available

Share Capital

Share Capital

Share allotments and capital structure

3 Allotments 30 Shares £30 Total
Date FromShare ClassShares AllottedAmount RaisedPrice/Share
18 Aug 201910£10£10
18 Aug 201910£10£10
4 Apr 201810£10£1

Officers

Officers

0 active 3 resigned
Status

No officers found

No officers found

Shareholders

Shareholders (7)

Thomas Jacques
25.0%
Ashirwad Merve
12.5%

Persons with Significant Control

Persons with Significant Control (0)

No PSC information available

Group Structure

Group Structure

No group structure identified

Charges

Charges

No charges registered

Properties

Properties

0 total

No related properties

Documents

Company Filings

DateCategoryDescriptionDocument
13 Apr 2026Confirmation StatementConfirmation statement made on 29 Mar 2026 with updates
31 Mar 2026OfficersAppointment of Dr Matthew Thomas Clarke as director on 31 Mar 2026
16 Dec 2025AccountsAnnual accounts made up to 31 Mar 2025
15 Dec 2025OfficersChange to director Dr Atul Kumar on 12 Dec 2025
9 Apr 2025Confirmation StatementConfirmation statement made on 29 Mar 2025 with no updates
13 Apr 2026 Confirmation Statement

Confirmation statement made on 29 Mar 2026 with updates

31 Mar 2026 Officers

Appointment of Dr Matthew Thomas Clarke as director on 31 Mar 2026

16 Dec 2025 Accounts

Annual accounts made up to 31 Mar 2025

15 Dec 2025 Officers

Change to director Dr Atul Kumar on 12 Dec 2025

9 Apr 2025 Confirmation Statement

Confirmation statement made on 29 Mar 2025 with no updates

Recent Activity

Latest Activity

Confirmation statement made on 29 Mar 2026 with updates

1 months ago on 13 Apr 2026

Appointment of Dr Matthew Thomas Clarke as director on 31 Mar 2026

1 months ago on 31 Mar 2026

Annual accounts made up to 31 Mar 2025

5 months ago on 16 Dec 2025

Change to director Dr Atul Kumar on 12 Dec 2025

5 months ago on 15 Dec 2025

Confirmation statement made on 29 Mar 2025 with no updates

1 years ago on 9 Apr 2025